Docoh
Loading...

ORTX Orchard Therapeutics

News

From Benzinga Pro
Orchard Therapeutics Highlights Publication In 'The Lancet' Of Long-Term Clinical Outcomes With Libmeldy For Treatment Of Children With Early-Onset Metachormatic Leukodystrophy
21 Jan 22
Biotech, News, FDA, General
Administration of one-time hematopoietic stem cell (HSC) gene therapy resulted in sustained, clinically meaningful benefits by preserving cognitive function and motor development in most patients 90% overall survival
Stocks That Hit 52-Week Lows On Wednesday
19 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Wednesday's morning trading, 400 companies set new 52-week lows.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
29 Dec 21
Pre-Market Outlook, Markets, Movers
Orchard Therapeutics Shares Spike To Session High On Volume As Traders Circulate Co. Website Showing Its Approach To Gene Therapy; BZ NOTE: BZ Newsdesk Cannot Confirm Timing Of/If Co. Website Was Updated Recently
16 Dec 21
Biotech, News, Rumors, FDA, Movers, Trading Ideas, General
https://www.orchard-tx.com/approach/gene-therapy/
Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2021
16 Nov 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
JP Morgan Downgrades Orchard Therapeutics to Underweight
16 Nov 21
News, Downgrades, Analyst Ratings
JP Morgan analyst Anupam Rama downgrades Orchard Therapeutics (NASDAQ:ORTX) from Neutral to Underweight.
Oppenheimer Maintains Outperform on Orchard Therapeutics, Lowers Price Target to $13
5 Nov 21
News, Price Target, Analyst Ratings
Oppenheimer analyst Kevin DeGeeter maintains Orchard Therapeutics (NASDAQ:ORTX) with a Outperform and lowers the price target from $15 to $13.
Orchard Therapeutics Q3 EPS $(0.29) Down From $(0.20) YoY
4 Nov 21
Earnings, News
Orchard Therapeutics (NASDAQ:ORTX) reported quarterly losses of $(0.29) per share. This is a 45 percent decrease over losses of $(0.20) per share from the same period last year.

Press releases

From Benzinga Pro
Orchard Therapeutics Announces Publication in The Lancet of Long-term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-onset MLD
21 Jan 22
Health Care, Analyst Ratings, Press Releases
Administration of one-time hematopoietic stem cell (HSC) gene therapy resulted in sustained, clinically meaningful benefits by preserving cognitive function and motor development in most patients 90% overall
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones
10 Jan 22
Health Care, Press Releases
Launch Momentum Building for Libmeldy® in Europe with Health Technology Assessments Progressing Favorably and Treatment Underway for Multiple Commercial Patients Initiating U.S. BLA Submission for OTL-200 as Early
Thinking about buying stock in Can Fite Biopharma, American Virtual Cloud Technologies, ShiftPixy, Siyata Mobile, or Orchard Therapeutics?
29 Dec 21
Opinion, Press Releases
NEW YORK, Dec. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CANF, AVCT, PIXY, SYTA, and ORTX.
Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates
4 Nov 21
Earnings, News, Health Care, Management, Press Releases
Updates from OTL-201 Clinical Proof-of-Concept Study in MPS-IIIA and OTL-204 Preclinical Study for GRN-FTD at ESGCT Showcase Potential for HSC Gene Therapy in Multiple Neurodegenerative Disorders Launch Activities for